Shanghai-based Ji Xing Pharmaceuticals, a company backed by RTW Investments, has announced a strategic collaboration agreement with Taiwan-headquartered TSH Biopharm (TSH). Under this agreement, TSH will provide commercialization support for varenicline solution nasal spray (US brand name Tyrvaya) in Taiwan. The financial details of the collaboration were not disclosed.
Varenicline Solution Nasal Spray: A Novel Treatment for Dry Eye Disease
Varenicline solution nasal spray, developed by Jixing’s partner Oyster Point Pharma, is a highly selective cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease as a preservative-free nasal spray. The product is designed to activate the trigeminal parasympathetic pathway, which increases the production of natural tears. Ji Xing holds exclusive rights to develop and commercialize this drug product in Greater China.
US FDA Approval and Clinical Urgency
Varenicline solution nasal spray received approval from the US FDA in October 2021, marking it as the first and only nasal spray for the treatment of dry eye disease signs and symptoms. In April 2023, the drug was applied in Boao Super Hospital as a clinically urgently needed import drug, highlighting its importance in addressing unmet medical needs in the treatment of dry eye disease.-Fineline Info & Tech
